SN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN38 is formed via hydrolysis of irinotecan by carboxylesterases and metabolized via glucuronidation by UGT1A1. The variant of UGT1A1 in ~10% of Caucasians which leads to poor metabolism of SN-38 predicts irinotecan toxicity, as it is then less easily excreted from the body in its SN-38 glucuronide form. SN-38 and its glucuronide are lost into the bile and intestines. It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan.

Mouse

Monoclonal Antibody

Protein G affinity purified

Liquid

ALL

ELISA

1:5000-1:20000

Shipped at 4°C. Store at -80℃~-20℃ for two year. Avoid freeze/thaw cycles.

PBS,PH7.4

SN-38 conjugated with BSA

1 mg/ml

Unconjugated

IgG1, k

MM48A

Fig1: ELISA Binding Assay of Anti-SN-38 Antibody to different proteins. ELISA analysis of Anti-SN38 Monoclonal Antibody with SN-38 -BSA, SN-38 ADC and BSA. Anti-SN-38 Monoclonal Antibody can bind to SN-38-BSA or SN-38 ADC but not carrier protein.

Fig2: ELISA Binding Assay of Anti-SN-38 Antibody Immobilized SN-38 ADC at 2μg/ /mL (100μL/well) can bind anti-SN-38 mouse monoclonal antibody .